Crescent Biopharma to Present at September Investor Conferences
Get Alerts CBIO Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:
- Cantor Global Healthcare Conference 2025, fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York.
- Morgan Stanley 23rd Annual Global Healthcare Conference, fireside chat on Monday, September 8, 2025, at 5:35 p.m. ET in New York.
A live webcast of each presentation will be available in the Investors section of the Company's website at https://investors.crescentbiopharma.com/news-events/events, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contact
Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cashelix Announces Audited CASX Token Presale with Fixed Hard Caps to Power Blockchain P2P Payments
- AI Has Made Media Pitching Noisier and Less Effective, Says Featured CEO Brett Farmiloe
- Allcredit.cards launches comprehensive database of 3,500 US credit cards
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share